Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
8057-65-6
Molecular formula
C197H188F19N41O28S6
Molecular weight
4131 g/mol
Drug class
Botanical topical preparationArnica montana extract, traditionally used as a counterirritant
Mechanism of action
The extract contains sesquiterpene lactones and other plant constituents with proposed local anti-inflammatory effects. The mechanism and clinical contribution of individual constituents are not fully established; topical use is associated with sensitisation risk.
Indications / reported uses
Traditional topical use for bruises, contusions and local muscle soreness in products authorised for external use; not for application to broken skin or mucous membranes unless the product label specifically permits
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Arnica Extract Environmental Risk Assessment (ERA) (the Arnica Extract ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.